A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the efficacy of ORMD-0801 compared to placebo on endogenous
glucose production in subjects with type 2 diabetes (T2DM). Subjects will undergo an initial
Screening Visit (Visit 0) to establish their eligibility to participate in the study. At
Visit 1 (2 weeks after the Screening Visit), qualifying subjects will be randomized to either
ORMD-0801 (8 mg) or matching placebo, study medication will be dispensed and subjects will
dose, twice a day, once in the morning prior to breakfast and once at night prior to bedtime